메뉴 건너뛰기




Volumn 7, Issue 1, 2011, Pages 183-192

Olmesartan/amlodipine: A review of its use in the management of hypertension

Author keywords

Antihypertensive monotherapy; BP control; BP goals; Combination therapy; Hypertension; Patients

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

EID: 79961196737     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S16852     Document Type: Review
Times cited : (29)

References (60)
  • 1
    • 0037010474 scopus 로고    scopus 로고
    • Selected major risk factors and global and regional burden of disease
    • Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347-1360.
    • (2002) Lancet , vol.360 , Issue.9343 , pp. 1347-1360
    • Ezzati, M.1    Lopez, A.D.2    Rodgers, A.3    Vander Hoorn, S.4    Murray, C.J.5
  • 2
    • 0003731907 scopus 로고    scopus 로고
    • Reducing Risks, Promoting Healthy Life
    • World Health Organization, Available at, Accessed September 17, 2008
    • World Health Organization. Reducing Risks, Promoting Healthy Life. The World Health Report. Available at: http://www.who.int/whr/2002/ en/whr02_en.pdf. Accessed September 17, 2008.
    • The World Health Report
  • 4
    • 33847633400 scopus 로고    scopus 로고
    • Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004
    • Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
    • (2007) Hypertension , vol.49 , Issue.1 , pp. 69-75
    • Ong, K.L.1    Cheung, B.M.2    Man, Y.B.3    Lau, C.P.4    Lam, K.S.5
  • 5
    • 0038047699 scopus 로고    scopus 로고
    • Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States
    • Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363-2369.
    • (2003) JAMA , vol.289 , Issue.18 , pp. 2363-2369
    • Wolf-Maier, K.1    Cooper, R.S.2    Banegas, J.R.3
  • 6
    • 44949104716 scopus 로고    scopus 로고
    • Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension
    • Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9): 1207-1225.
    • (2008) Drugs , vol.68 , Issue.9 , pp. 1207-1225
    • Smith, D.H.1
  • 7
    • 0029886630 scopus 로고    scopus 로고
    • Blood pressure as a cardiovascular risk factor: Prevention and treatment
    • Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275(20):1571-1576.
    • (1996) JAMA , vol.275 , Issue.20 , pp. 1571-1576
    • Kannel, W.B.1
  • 8
    • 0030034592 scopus 로고    scopus 로고
    • Blood pressure and end-stage renal disease in men
    • Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18.
    • (1996) N Engl J Med , vol.334 , Issue.1 , pp. 13-18
    • Klag, M.J.1    Whelton, P.K.2    Randall, B.L.3
  • 9
    • 70449851433 scopus 로고    scopus 로고
    • Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document
    • Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27: 2121-2158.
    • (2009) J Hypertens , vol.27 , pp. 2121-2158
    • Mancia, G.1    Laurent, S.2    Agabiti-Rosei, E.3
  • 10
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23): 2981-2997.
    • (2002) JAMA , vol.288 , Issue.23 , pp. 2981-2997
  • 11
    • 62849090492 scopus 로고    scopus 로고
    • Hypertension Improvement Project (HIP): Study protocol and implementation challenges
    • Dolor RJ, Yancy WS Jr, Owen WF, et al. Hypertension Improvement Project (HIP): study protocol and implementation challenges. Trials. 2009;10:13.
    • (2009) Trials , vol.10 , pp. 13
    • Dolor, R.J.1    Yancy Jr., W.S.2    Owen, W.F.3
  • 12
    • 0030056841 scopus 로고    scopus 로고
    • New meta-analysis of treatment trials of hypertension: Improving the estimate of therapeutic benefit
    • Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens. 1996;10(1):1-8.
    • (1996) J Hum Hypertens , vol.10 , Issue.1 , pp. 1-8
    • Gueyffier, F.1    Froment, A.2    Gouton, M.3
  • 13
    • 0031044480 scopus 로고    scopus 로고
    • Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
    • Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277(9):739-745.
    • (1997) JAMA , vol.277 , Issue.9 , pp. 739-745
    • Psaty, B.M.1    Smith, N.L.2    Siscovick, D.S.3
  • 14
    • 0025831464 scopus 로고
    • Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group
    • SHEP Cooperative Research Group
    • SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24):3255-3264.
    • (1991) JAMA , vol.265 , Issue.24 , pp. 3255-3264
  • 15
    • 33846485050 scopus 로고    scopus 로고
    • Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States
    • Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167(2):141-147.
    • (2007) Arch Intern Med , vol.167 , Issue.2 , pp. 141-147
    • Wang, Y.R.1    Alexander, G.C.2    Stafford, R.S.3
  • 16
    • 9144248446 scopus 로고    scopus 로고
    • Hypertension treatment and control in five European countries, Canada, and the United States
    • Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17.
    • (2004) Hypertension , vol.43 , Issue.1 , pp. 10-17
    • Wolf-Maier, K.1    Cooper, R.S.2    Kramer, H.3
  • 17
    • 36649026223 scopus 로고    scopus 로고
    • Achieving blood pressure goals: Why aren't we?
    • Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich). 2006;8(12):865-872.
    • (2006) J Clin Hypertens (Greenwich) , vol.8 , Issue.12 , pp. 865-872
    • Cushman, W.C.1    Basile, J.2
  • 19
    • 2942750248 scopus 로고    scopus 로고
    • Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension
    • Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med. 2004;117(1): 14-18.
    • (2004) Am J Med , vol.117 , Issue.1 , pp. 14-18
    • Spranger, C.B.1    Ries, A.J.2    Berge, C.A.3    Radford, N.B.4    Victor, R.G.5
  • 20
    • 5444220883 scopus 로고    scopus 로고
    • Pharmacogenetics of antihypertensive drug response
    • Kreutz R. Pharmacogenetics of antihypertensive drug response. Curr Hypertens Rep. 2004;6(1):15-20.
    • (2004) Curr Hypertens Rep , vol.6 , Issue.1 , pp. 15-20
    • Kreutz, R.1
  • 21
    • 0032882634 scopus 로고    scopus 로고
    • Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management
    • Neutel JM. Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens. 1999;12(8 Pt 2):73S-79S.
    • (1999) Am J Hypertens , vol.12 , Issue.8 PART 2
    • Neutel, J.M.1
  • 22
    • 61649091385 scopus 로고    scopus 로고
    • Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials
    • Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3): 290-300.
    • (2009) Am J Med , vol.122 , Issue.3 , pp. 290-300
    • Wald, D.S.1    Law, M.2    Morris, J.K.3    Bestwick, J.P.4    Wald, N.J.5
  • 23
    • 24644443331 scopus 로고    scopus 로고
    • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
    • Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
    • (2005) Lancet , vol.366 , Issue.9489 , pp. 895-906
    • Dahlof, B.1    Sever, P.S.2    Poulter, N.R.3
  • 24
    • 57349138291 scopus 로고    scopus 로고
    • Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    • Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
    • (2008) N Engl J Med , vol.359 , Issue.23 , pp. 2417-2428
    • Jamerson, K.1    Weber, M.A.2    Bakris, G.L.3
  • 25
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426): 2022-2031.
    • (2004) Lancet , vol.363 , Issue.9426 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3
  • 26
    • 77951735232 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure control in type 2 diabetes mellitus
    • Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-1585.
    • (2010) N Engl J Med , vol.362 , Issue.17 , pp. 1575-1585
    • Cushman, W.C.1    Evans, G.W.2    Byington, R.P.3
  • 28
    • 68149162414 scopus 로고    scopus 로고
    • Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension
    • Bramlage P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2009;10(11): 1755-1767.
    • (2009) Expert Opin Pharmacother , vol.10 , Issue.11 , pp. 1755-1767
    • Bramlage, P.1
  • 29
    • 77149134656 scopus 로고    scopus 로고
    • The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm
    • Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin Exp Hypertens. 2010;32(1):35-42.
    • (2010) Clin Exp Hypertens , vol.32 , Issue.1 , pp. 35-42
    • Schmieder, R.E.1
  • 30
    • 74949125742 scopus 로고    scopus 로고
    • Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis
    • Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
    • (2010) Hypertension , vol.55 , Issue.2 , pp. 399-407
    • Gupta, A.K.1    Arshad, S.2    Poulter, N.R.3
  • 31
    • 0037490085 scopus 로고    scopus 로고
    • Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials
    • Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J. 2003;326(7404):1427.
    • (2003) Br Med J , vol.326 , Issue.7404 , pp. 1427
    • Law, M.R.1    Wald, N.J.2    Morris, J.K.3    Jordan, R.E.4
  • 32
    • 0028845276 scopus 로고
    • Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebocontrolled, parallel-group study. The Benazepril/Amlodipine Study Group
    • Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebocontrolled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol. 1995;35(11):1060-1066.
    • (1995) J Clin Pharmacol , vol.35 , Issue.11 , pp. 1060-1066
    • Frishman, W.H.1    Ram, C.V.2    McMahon, F.G.3
  • 33
    • 0030513239 scopus 로고    scopus 로고
    • Treatment of patients with essential hypertension: Amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo
    • Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther. 1996;18(6):1213-1224.
    • (1996) Clin Ther , vol.18 , Issue.6 , pp. 1213-1224
    • Kuschnir, E.1    Acuna, E.2    Sevilla, D.3
  • 34
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15): 1547-1559.
    • (2008) N Engl J Med , vol.358 , Issue.15 , pp. 1547-1559
    • Yusuf, S.1    Teo, K.K.2    Pogue, J.3
  • 36
    • 33748930983 scopus 로고    scopus 로고
    • National Institute for Health and Clinical Excellence, Available at, Accessed June 9, 2010
    • National Institute for Health and Clinical Excellence. Hypertension: Management of hypertension in adults in primary care. Available at: http://www.nice.org.uk/nicemedia/live/10986/30114/30114.pdf. Accessed June 9, 2010.
    • Hypertension: Management of hypertension in adults in primary care
  • 37
    • 34250370923 scopus 로고    scopus 로고
    • Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring
    • Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25(7):1327-1336.
    • (2007) J Hypertens , vol.25 , Issue.7 , pp. 1327-1336
    • Fabia, M.J.1    Abdilla, N.2    Oltra, R.3    Fernandez, C.4    Redon, J.5
  • 38
    • 77149136418 scopus 로고    scopus 로고
    • Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans
    • Coltamai L, Maillard M, Simon A, Vogt B, Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens. 2010;28(3): 520-526.
    • (2010) J Hypertens , vol.28 , Issue.3 , pp. 520-526
    • Coltamai, L.1    Maillard, M.2    Simon, A.3    Vogt, B.4    Burnier, M.5
  • 39
    • 28144458569 scopus 로고    scopus 로고
    • Sustained 24-hour blockade of the renin-angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor
    • Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther. 2005;78(5):501-507.
    • (2005) Clin Pharmacol Ther , vol.78 , Issue.5 , pp. 501-507
    • Hasler, C.1    Nussberger, J.2    Maillard, M.3    Forclaz, A.4    Brunner, H.R.5    Burnier, M.6
  • 40
    • 34547454237 scopus 로고    scopus 로고
    • Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake
    • Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens. 2007;20(8): 907-916.
    • (2007) Am J Hypertens , vol.20 , Issue.8 , pp. 907-916
    • Jones, M.R.1    Sealey, J.E.2    Laragh, J.H.3
  • 41
    • 0043172552 scopus 로고    scopus 로고
    • Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension
    • Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23(7):419-430.
    • (2003) Clin Drug Invest , vol.23 , Issue.7 , pp. 419-430
    • Brunner, H.R.1    Stumpe, K.O.2    Januszewicz, A.3
  • 42
    • 0034760610 scopus 로고    scopus 로고
    • Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
    • Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5): 283-291, 318.
    • (2001) J Clin Hypertens (Greenwich) , vol.3 , Issue.5
    • Oparil, S.1    Williams, D.2    Chrysant, S.G.3    Marbury, T.C.4    Neutel, J.5
  • 43
    • 12744269551 scopus 로고    scopus 로고
    • Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan
    • Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5(1):41-50.
    • (2005) Am J Cardiovasc Drugs , vol.5 , Issue.1 , pp. 41-50
    • Smith, D.H.1    Dubiel, R.2    Jones, M.3
  • 44
    • 44949171907 scopus 로고    scopus 로고
    • Olmesartan medoxomil: A review of its use in the management of hypertension
    • Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9): 1239-1272.
    • (2008) Drugs , vol.68 , Issue.9 , pp. 1239-1272
    • Scott, L.J.1    McCormack, P.L.2
  • 45
    • 0029049389 scopus 로고
    • Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease
    • Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995;50(3):560-586.
    • (1995) Drugs , vol.50 , Issue.3 , pp. 560-586
    • Haria, M.1    Wagstaff, A.J.2
  • 46
    • 43549100189 scopus 로고    scopus 로고
    • The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study
    • Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587-604.
    • (2008) Clin Ther , vol.30 , Issue.4 , pp. 587-604
    • Chrysant, S.1    Melino, M.2    Karki, S.3    Lee, J.4    Heyrman, R.5
  • 47
    • 73349111840 scopus 로고    scopus 로고
    • Onset of antihypertensive effect in patients with mild-to-severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placebo
    • Chrysant S, Melino M, Karki S, Lee J, Heyrman R. Onset of antihypertensive effect in patients with mild-to-severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placebo. J Clin Hypertens. 2008a;26:378 Suppl 1:378.
    • (2008) J Clin Hypertens , vol.26 , Issue.378 SUPPL. 1 , pp. 378
    • Chrysant, S.1    Melino, M.2    Karki, S.3    Lee, J.4    Heyrman, R.5
  • 48
    • 74349114056 scopus 로고    scopus 로고
    • Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use
    • Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54(5):427-436.
    • (2009) J Cardiovasc Pharmacol , vol.54 , Issue.5 , pp. 427-436
    • Oparil, S.1    Lee, J.2    Karki, S.3    Melino, M.4
  • 49
    • 57449086215 scopus 로고    scopus 로고
    • Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study
    • Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(1):11-25.
    • (2009) Clin Drug Investig , vol.29 , Issue.1 , pp. 11-25
    • Volpe, M.1    Brommer, P.2    Haag, U.3    Miele, C.4
  • 50
    • 67650302856 scopus 로고    scopus 로고
    • Olmesartan medoxomil plus amlodipine increases eff icacy in patients with moderate-to-severe hypertension after monotherapy: A randomized, double-blind, parallel-group, multicentre study
    • Barrios V, Brommer P, Haag U, Calderon A, Escobar C. Olmesartan medoxomil plus amlodipine increases eff icacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(7):427-439.
    • (2009) Clin Drug Investig , vol.29 , Issue.7 , pp. 427-439
    • Barrios, V.1    Brommer, P.2    Haag, U.3    Calderon, A.4    Escobar, C.5
  • 51
    • 84868588276 scopus 로고    scopus 로고
    • Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy (late breaker at the American Society of Hypertension 25th Annual Scentific Meeting, New York)
    • Weir MR, Hsueh WA, Nesbitt SD, et al. Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy (late breaker at the American Society of Hypertension 25th Annual Scentific Meeting, New York). J Clin Hypertens (Greenwich). 2010;12(7):536.
    • (2010) J Clin Hypertens (Greenwich) , vol.12 , Issue.7 , pp. 536
    • Weir, M.R.1    Hsueh, W.A.2    Nesbitt, S.D.3
  • 52
    • 77955396612 scopus 로고    scopus 로고
    • Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study
    • Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis. 2010;4(4):209-221.
    • (2010) Ther Adv Cardiovasc Dis , vol.4 , Issue.4 , pp. 209-221
    • Punzi, H.1    Neutel, J.M.2    Kereiakes, D.J.3
  • 53
    • 70349973807 scopus 로고    scopus 로고
    • Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension
    • Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich). 2009;11(9):475-482.
    • (2009) J Clin Hypertens (Greenwich) , vol.11 , Issue.9 , pp. 475-482
    • Chrysant, S.G.1    Oparil, S.2    Melino, M.3    Karki, S.4    Lee, J.5    Heyrman, R.6
  • 54
    • 75749092819 scopus 로고    scopus 로고
    • Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension
    • Heagerty AM, Laeis P, Haag U. Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens. 2009;27 Suppl 4:S283.
    • (2009) J Hypertens , vol.27 , Issue.SUPPL. 4
    • Heagerty, A.M.1    Laeis, P.2    Haag, U.3
  • 55
    • 84898892067 scopus 로고    scopus 로고
    • Olmesartan medoxomil/amlodipine (OLM/AML) improves blood pressure (BP) control throughout 24 hours compared with AML monotherapy in patients with moderate-to-severe hypertension
    • Parati G, Bilo G. Olmesartan medoxomil/amlodipine (OLM/AML) improves blood pressure (BP) control throughout 24 hours compared with AML monotherapy in patients with moderate-to-severe hypertension. J Hypertens. 2010;28:e111.
    • (2010) J Hypertens , vol.28
    • Parati, G.1    Bilo, G.2
  • 56
    • 75749092819 scopus 로고    scopus 로고
    • Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension
    • Heagerty AM, Laeis P, Haag U. Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens. 2009;27 Suppl 4:S283.
    • (2009) J Hypertens , vol.27 , Issue.SUPPL. 4
    • Heagerty, A.M.1    Laeis, P.2    Haag, U.3
  • 57
    • 67549119235 scopus 로고    scopus 로고
    • Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: An open-label, long-term study
    • Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig. 2009;29(6):381-391.
    • (2009) Clin Drug Investig , vol.29 , Issue.6 , pp. 381-391
    • Volpe, M.1    Miele, C.2    Haag, U.3
  • 58
    • 67549116889 scopus 로고    scopus 로고
    • Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: Post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study
    • Mourad JJ, Le Jeune S. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(6):419-425.
    • (2009) Clin Drug Investig , vol.29 , Issue.6 , pp. 419-425
    • Mourad, J.J.1    Le Jeune, S.2
  • 59
    • 84898855739 scopus 로고    scopus 로고
    • Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy
    • New York, Presented as a
    • Weir M, Hsueh WA, Nesbitt SD, et al. Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy. 2010: Presented as a late breaker at the American Society of Hypertension 25th Annual Scentific Meeting and Exposition 2010: New York.
    • (2010) Late breaker at the American Society of Hypertension 25th Annual Scentific Meeting and Exposition 2010
    • Weir, M.1    Hsueh, W.A.2    Nesbitt, S.D.3
  • 60
    • 0031018599 scopus 로고    scopus 로고
    • Pharmacological differences between calcium antagonists
    • Opie LH. Pharmacological differences between calcium antagonists. Eur Heart J. 1997;18 Suppl A:A71-A79.
    • (1997) Eur Heart J , vol.18 , Issue.SUPPL. A
    • Opie, L.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.